Neurohumoral and inflammatory activation in patients with coronary artery disease treated with statins

Heart

Volumn 92, Issue 12, 2006, Pages 1858-1859

  Van De Veire, N R ^a,c   Philippe J ^a   De Winter, O ^a   Langlois, M ^b   Bernard, D ^b   De Sutter, J ^a  

^a GHENT UNIVERSITY   (Belgium)

^b AZ Sint Jan ^*  (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROHORMONE; PRAVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR;

AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; HEART EJECTION FRACTION; HUMAN; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-6; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845195345     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.084368     Document Type: Article

References (5)

1. Feuerstein GZ, Libby P, Mann DL. Inflammation and cardiac diseases. Basel - Boston - Berlin: Birkhäuser Verlag, 2003:1-5.
2. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-05.
3. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8.
4. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein and coronary artery disease. N Engl J Med 2005;352:29-38.
5. Ray KK, Cannon CP, Cairns R, et al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT - TIMI 22 trial. J Am Coll Cardiol 2005;46:1417-24.